Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

How Damaging Immune Cells Develop During Tuberculosis

By PLOS | September 4, 2018

Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.

Foam cells are a type of white blood cell, known as macrophages, that have accumulated fatty, waxy, or oily compounds called lipids. These cells contribute to maladaptive immune responses such as chronic inflammation and tissue damage in a variety of diseases. The formation of foam cells has been most thoroughly studied in the context of atherosclerosis, or hardening of the arteries. During atherosclerosis, macrophages develop into foam cells by accumulating a waxy, fat-like substance called cholesterol. But it has been unclear how these cells form during chronic infectious diseases such as tuberculosis — a contagious and often severe airborne disease caused by infection with Mycobacterium tuberculosis bacteria.

Gennaro and colleagues provide evidence that foam cells in lung tissue from rabbits, non-human primates, and humans with tuberculosis form by primarily accumulating a type of fat called triglycerides, rather than cholesterol as seen in atherosclerosis. Moreover, triglyceride accumulation in human macrophages infected with M. tuberculosis is mediated by distinct signaling pathways from those associated with cholesterol storage in macrophages during atherosclerosis. The findings demonstrate that foam cells store different types of lipids and form through distinct mechanisms, depending on the disease.

According to the authors, the findings may have translational implications. For example, molecules involved in triglyceride synthesis may be used as novel biomarkers of progression to active tuberculosis. In addition, manipulating factors that affect macrophage lipid content might be an effective way to treat tuberculosis. Because many of these factors have been extensively studied in the context of cancer, cardiovascular diseases, and metabolic diseases, it may be possible to repurpose pharmacological compounds as therapies against tuberculosis. Such therapies may shorten the duration of antibiotic regimens and help restrict the emergence of antibiotic resistance.

“The finding that foam cells found in tuberculosis differ from those present in atherosclerosis,” states Gennaro, “demonstrates that these dysfunctional cells, which are associated with many diseases, are generated through biological processes that differ from one disease to another.”

SOURCE: PLOS


Filed Under: Infectious Disease

 

Related Articles Read More >

Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters
Vaccine
FDA greenlights 786,000 additional monkeypox vaccine doses

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50